Letter: sequential or combined systemic treatment for unresectable hepatocellular carcinoma-authors' reply

被引：0
|
作者：
Kirstein, Martha M. [1 ,2 ]
Scheiner, Bernhard [3 ]
Pinter, Matthias [3 ]
Vogel, Arndt [1 ]
机构：
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[2] Univ Med Ctr Schleswig Holstein, Dept Med 1, Lubeck, Germany
[3] Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, Vienna, Austria
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2020年 / 52卷 / 05期
关键词：
SORAFENIB;
D O I：
10.1111/apt.15980
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LINKED CONTENT This article is linked to Kirstein et al and Mo et al papers. To view these articles, visit and
引用
收藏
页码：917 / 918
页数：2
相关论文
共 50 条
  • [21] Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma
    Becker, Gerhild
    Soezgen, Tarik
    Olschewski, Manfred
    Laubenberger, Joerg
    Blum, Hubert Erich
    Allgaier, Hans-Peter
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (39) : 6104 - 6109
  • [22] Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma
    Shimose, Shigeo
    Hiraoka, Atsushi
    Tanaka, Masatoshi
    Iwamoto, Hideki
    Tanaka, Takaaki
    Noguchi, Kazunori
    Aino, Hajime
    Yamaguchi, Taizo
    Itano, Satoshi
    Suga, Hideya
    Niizeki, Takashi
    Moriyama, Etsuko
    Shirono, Tomotake
    Noda, Yu
    Kamachi, Naoki
    Okamura, Shusuke
    Nakano, Masahito
    Kawaguchi, Takumi
    Kuromatsu, Ryoko
    Koga, Hironori
    Torimura, Takuji
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [23] Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma
    Shigeo Shimose
    Atsushi Hiraoka
    Masatoshi Tanaka
    Hideki Iwamoto
    Takaaki Tanaka
    Kazunori Noguchi
    Hajime Aino
    Taizo Yamaguchi
    Satoshi Itano
    Hideya Suga
    Takashi Niizeki
    Etsuko Moriyama
    Tomotake Shirono
    Yu Noda
    Naoki Kamachi
    Shusuke Okamura
    Masahito Nakano
    Takumi Kawaguchi
    Ryoko Kuromatsu
    Hironori Koga
    Takuji Torimura
    Scientific Reports, 12
  • [24] SEQUENTIAL SYSTEMIC THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN THE ERA OF IMMUNOTHERAPY: WHAT COMES NEXT?
    Cabibbo, Giuseppe
    Celsa, Ciro
    Rizzo, Giacomo
    Battaglia, Salvatore
    Enea, Marco
    Camma, Calogero
    HEPATOLOGY, 2020, 72 : 707A - 708A
  • [25] Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies
    Sun W.
    Cabrera R.
    Journal of Gastrointestinal Cancer, 2018, 49 (2) : 107 - 115
  • [26] Combined versus single locoregional therapy in the treatment of unresectable hepatocellular carcinoma
    Othman, Moustafa H. M.
    Mourad, Amr F.
    Abd Ellah, Mohamed M. H.
    Imam, Hala M. K.
    EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE, 2014, 45 (02): : 395 - 401
  • [27] Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
    Huang, Kuo-Wei
    Lee, Pei-Chang
    Chao, Yee
    Su, Chien-Wei
    Lee, I-Cheng
    Lan, Keng-Hsin
    Chu, Chi-Jen
    Hung, Yi-Ping
    Chen, San-Chi
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [28] Issue on combined locoregional and systemic treatment for hepatocellular carcinoma
    Wu, Yi-Chia
    Wakil, Ali
    Salomon, Fayssa
    Pyrsopoulos, Nikolaos
    HEPATOMA RESEARCH, 2023, 9
  • [29] Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation - authors' reply
    Cabibbo, G.
    Genco, C.
    Camma, C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (07) : 862 - 863
  • [30] Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. Authors' reply
    Vilar-Gomez, Eduardo
    Chalasani, Naga
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (07) : 838 - 839
12345